Recently released market study: Hepatitis - Pipeline Review, H2 2012

Sept. 28, 2012 - PRLog -- Global Markets Direct's, 'Hepatitis - Pipeline Review, H2 2012', provides an overview of the Hepatitis therapeutic pipeline. This report provides information on the therapeutic development for Hepatitis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatitis. 'Hepatitis - Pipeline Review, H2 2012' is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team.

------------------------------------------------------------
Full Report Details at
- http://www.fastmr.com/prod/463819_hepatitis_pipeline_review_h2_2012.aspx
------------------------------------------------------------

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

* A snapshot of the global therapeutic scenario for Hepatitis.
* A review of the Hepatitis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
* Coverage of products based on various stages of development ranging from discovery till registration stages.
* A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
* Coverage of the Hepatitis pipeline on the basis of route of administration and molecule type.
* Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
* Key discontinued pipeline projects.
* Latest news and deals relating to the products.

Reasons to buy

* Identify and understand important and diverse types of therapeutics under development for Hepatitis.
* Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
* Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
* Devise corrective measures for pipeline projects by understanding Hepatitis pipeline depth and focus of Hepatitis therapeutics.
* Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
* Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Keywords

Hepatitis Therapeutic Products under Development, Key Players in Hepatitis Therapeutics, Hepatitis Pipeline Overview, Hepatitis Pipeline, Hepatitis Pipeline Assessment

Partial Table of Contents:

Table of Contents
Table of Contents
List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Hepatitis Overview
Therapeutics Development
An Overview of Pipeline Products for Hepatitis
Hepatitis Therapeutics under Development by Companies
Hepatitis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Hepatitis Therapeutics - Products under Development by Companies
Hepatitis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Hepatitis Therapeutics Development
Bristol-Myers Squibb Company
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Abbott Laboratories
United Therapeutics Corporation
Medgenics Inc.
Valeant Pharmaceuticals International
GlaxoSmithKline plc
Tekmira Pharmaceuticals Corp.
Inovio Biomedical Corporation
Idenix Pharmaceuticals, Inc.
Gilead Sciences, Inc.
Merck & Co., Inc.
Lentigen Corporation
BioLineRx, Ltd.
Celltrion, Inc.
Ambrilia Biopharma Inc.
Biotron Limited
Novartis AG
Achillion Pharmaceuticals, Inc.
Human Genome Sciences, Inc.
InterMune, Inc.
Ono Pharmaceutical Co., Ltd.
Pfizer Inc.
SuperGen, Inc.
Toyama Chemical Co. Ltd
Vertex Pharmaceuticals Incorporated
Genmab A/S
Santaris Pharma A/S
Tacere Therapeutics, Inc.
Aduro BioTech
Alfacell Corporation
CEL-SCI Corporation
Crucell N.V.
Celgene Corporation
Zosano Pharma, Inc.
4SC AG
EpiCept Corporation
Hemispherx Biopharma, Inc.
Agenix Limited
Immtech Pharmaceuticals, Inc.
Can-Fite BioPharma Ltd.
Arrowhead Research Corporation
Ligand Pharmaceuticals Incorporated
Medivir AB
Benitec Ltd.
BioDiem Ltd
Biota Holdings Limited
NanoViricides, Inc.
Novelos Therapeutics, Inc.
Patrys Limited
Peregrine Pharmaceuticals, Inc.
CytoGenix, Inc.
Amarillo Biosciences, Inc.
BioCryst Pharmaceuticals, Inc.
Flamel Technologies S.A.
Dynavax Technologies Corporation
Transgene SA
Lipoxen PLC
Bukwang Pharmaceutical Co., Ltd.
Miraca Holdings Inc.
Green Cross Corporation
Hanall Pharmaceutical Co., Ltd.
MOLOGEN AG
LG Life Sciences, Ltd
Samaritan Pharmaceuticals, Inc.
LTT Bio-Pharma Co., Ltd.
Uni-Bio Science Group Ltd.
Panacea Biotec Limited
Summit Corporation plc
Phynova Group Ltd
Tripep AB
Digna Biotech, S.L.
Debiopharm Group
Immune Network Research Ltd.
StemCells, Inc.
Colby Pharmaceutical Company
Maywufa Company Limited
SCYNEXIS, Inc.
Nutri Pharma ASA
Mucosis B.V.
Biolex Therapeutics, Inc.
Cytheris SA
Altor BioScience Corporation
Eiger BioPharmaceuticals, Inc.
AiCuris GmbH & Co. KG
Okairos
GeneScience Pharmaceuticals Co., Ltd.
PTC Therapeutics, Inc.
Conatus Pharmaceuticals Inc.
Presidio Pharmaceuticals, Inc.
Romark Laboratories, L.C.
Chimerix, Inc.
Phage Biotechnology Corporation
Intarcia Therapeutics, Inc.
REPLICor Inc.
Biotica Technology Ltd

Full Table of Contents is available at:
-- http://www.fastmr.com/catalog/product.aspx?productid=4638...

About Global Markets Direct

Global Markets Direct is a leading provider of global business intelligence and market analysis. It publishes a range of high quality company and market reports created by its large research and analysis capability and drawing from its extensive unique databases of industry-specific information.